Contact
searchSearch
HMP Global
Login

Psych Congress Network

Latest News, Insights, and Quizzes

Headshot of Snoben Kuruvila
Videos
Emerging Rapid-Acting Intervention Options for the Treatment of MDD
04/24/2025
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session...
04/24/2025
Psych Congress Network
open and spilled bottle of pills
News
Beta-Blockers Ineffective for Treating Psychological Symptoms of Anxiety
04/24/2025
Maria Mantas
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no...
04/24/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
person holding cannabis
Cannabis Use Requiring Acute Care Increases Dementia Risk
04/22/2025
Jolynn Tumolo
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older...
04/22/2025
Neurology
From Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
From Neurology
Expert Insights Quiz
Expert Insights Quiz
Effective Strategies to Introduce LAIs to Patients In-Person and Via Telemedicine
04/21/2025
Craig Chepke, MD, DFAPA
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following...
04/21/2025
Psych Congress Network
a dialogue bubble with the word "quiz"
Quiz
How do inpatient addiction consultation services impact MOUD initiation?
04/21/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
04/21/2025
Psych Congress Network
strand of DNA
News
Genetic Liability for Schizophrenia May Affect Traumatic Brain Injury Associations
04/21/2025
Jolynn Tumolo
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for...
04/21/2025
Psych Congress Network
injection for schizophrenia treatment
News
Antipsychotic Sedation Peaks in First 2 Weeks, Emphasizing Importance of Early Monitoring
04/21/2025
Maria Mantas
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized...
04/21/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
older woman with depression
News
Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds
04/16/2025
Maria Mantas
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found...
04/16/2025
Psych Congress Network

Latest Expert Insights

Headshot of Snoben Kuruvila
Videos
Emerging Rapid-Acting Intervention Options for the Treatment of MDD
04/24/2025
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session...
04/24/2025
Psych Congress Network
Dr Rakesh Jain
Podcasts
Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
04/17/2025
Rakesh Jain, MD, MPH, RD
Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.
Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.
Join Rakesh Jain, MD, MPH, as he...
04/17/2025
Psych Congress Network
Dr Greg Mattingly
Podcasts
Viloxazine ER: A New Era in ADHD Treatment?
04/17/2025
Greg Mattingly, MD
Join Greg Mattingly, MD, as he discusses the evolving ADHD treatment landscape, in particular extended-release viloxazine
Join Greg Mattingly, MD, as he discusses the evolving ADHD treatment landscape, in particular extended-release viloxazine
Join Greg Mattingly, MD, as he...
04/17/2025
Psych Congress Network
headshot of Dr Craig Chepke
Videos
Effective Communication Strategies for Introducing LAIs in Telemedicine Settings
04/16/2025
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.
In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.
In this video, Craig Chepke, MD,...
04/16/2025
Psych Congress Network
headshot of Dr Mohamed Abdelwahab
Q&As
OSA Treatment Outcomes Highlight Impact of Interdisciplinary Care
04/15/2025
Mohamed Abdelwahab, MD, PhD
Mohamed A. Abdelwahab, MD, PhD, discusses his recent meta-analysis comparing the mental health impacts of CPAP and surgical interventions.
Mohamed A. Abdelwahab, MD, PhD, discusses his recent meta-analysis comparing the mental health impacts of CPAP and surgical interventions.
Mohamed A. Abdelwahab, MD, PhD,...
04/15/2025
Psych Congress Network
headshot of Dr Julie Carbray
Q&As
How Clinicians Can Navigate Stimulant vs Nonstimulant Treatments for ADHD
04/11/2025
Julie A. Carbray, PhD, APRN
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute...
04/11/2025
Psych Congress NP Institute
Kristian Dambrino, MSN
Videos
When Monotherapy Doesn’t Work: Treatment Resistance in Tardive Dyskinesia
04/08/2025
Kristian Dambrino, MSN, APRN, PMHNP
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member...
04/08/2025
Psych Congress Network
Rakesh and Craig
Podcasts
Weighing the Options: Medication, Lifestyle, and the Path to Wellness
03/26/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain...
03/26/2025
Psych Congress Network
Raj K. Kalapatapu, MD, PhD
KOL Perspective
Selecting a Medication From Within a Therapeutic Class of Psychotropic Medications
03/20/2025
the right psychotropic medication can be challenging, but Raj K. Kalapatapu, MD, PhD, an Associate Professor of Psychiatry at UCSF, offers a practical framework to simplify the process.
the right psychotropic medication can be challenging, but Raj K. Kalapatapu, MD, PhD, an Associate Professor of Psychiatry at UCSF, offers a practical framework to simplify the process.
the right psychotropic...
03/20/2025
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
A Psychiatrist’s Role in Tackling Sleep-Wake Disorders
03/18/2025
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores...
03/18/2025
Psych Congress Network

From the Newsrooms

Headshot of Snoben Kuruvila
Videos
Emerging Rapid-Acting Intervention Options for the Treatment of MDD
04/24/2025
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session...
04/24/2025
Psych Congress Network
headshot of Dr Julie Carbray
Q&As
How Clinicians Can Navigate Stimulant vs Nonstimulant Treatments for ADHD
04/11/2025
Julie A. Carbray, PhD, APRN
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute...
04/11/2025
Psych Congress NP Institute
Kristian Dambrino, MSN
Videos
When Monotherapy Doesn’t Work: Treatment Resistance in Tardive Dyskinesia
04/08/2025
Kristian Dambrino, MSN, APRN, PMHNP
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member...
04/08/2025
Psych Congress Network
Andrew Penn
Clinical Pearls
Building a Strong Foundation Through Neurobiology
03/30/2025
Andrew Penn, RN, MS, NP, CNS, APRN-BC
In this interview from the NP Institute annual meeting, Co-Chair Andrew Penn, NP, discusses the importance of neurobiological foundations in everyday prescribing.
In this interview from the NP Institute annual meeting, Co-Chair Andrew Penn, NP, discusses the importance of neurobiological foundations in everyday prescribing.
In this interview from the NP...
03/30/2025
Psych Congress NP Institute
(Left to right) Moushumi Mukerji, MSN, PMHNP-BC, CNM and Vanessa Joy Walker, CPC, MPH Candidate.
Clinical Pearls
Clarifying Common Misconceptions About Treating Anxiety in Women
03/30/2025
Anxiety in women is often misunderstood—even in psychiatric clinical settings. Ahead of the 2025 Psych Congress NP Institute, Psych Congress Network connected with Moushumi Mukerji, MSN, PMHNP-BC, CNM, to discuss some of the key clinical...
Anxiety in women is often misunderstood—even in psychiatric clinical settings. Ahead of the 2025 Psych Congress NP Institute, Psych Congress Network connected with Moushumi Mukerji, MSN, PMHNP-BC, CNM, to discuss some of the key clinical...
Anxiety in women is often...
03/30/2025
Psych Congress NP Institute
(Left to right) Moushumi Mukerji, MSN, PMHNP-BC, CNM and Vanessa Joy Walker, CPC, MPH Candidate.
Clinical Pearls
Adopting a Life-Stage Lens for Anxiety Treatment in Women
03/29/2025
Moushumi Mukerji, MSN, PMHNP-BC, CNM, and Vanessa Joy Walker, CPC, MPH Candidate discuss some of the key clinical takeaways from their session on treating anxiety in women patients, presented at the 2025 Psych Congress NP Institute.
Moushumi Mukerji, MSN, PMHNP-BC, CNM, and Vanessa Joy Walker, CPC, MPH Candidate discuss some of the key clinical takeaways from their session on treating anxiety in women patients, presented at the 2025 Psych Congress NP Institute.
Moushumi Mukerji, MSN, PMHNP-BC,...
03/29/2025
Psych Congress NP Institute
Chelsie Monroe and Desiree Matthews
APP Perspectives
How Psychiatric NPs Can Broaden Their Career Horizons
03/28/2025
Psych Congress NP Institute Steering Committee Members Chelsie Monroe, PMHNP-BC, APN, and Desiree Matthews, PMHNP-BC, reflect on the lessons they wish they’d learned earlier in their NP careers and offer practical advice for those whose...
Psych Congress NP Institute Steering Committee Members Chelsie Monroe, PMHNP-BC, APN, and Desiree Matthews, PMHNP-BC, reflect on the lessons they wish they’d learned earlier in their NP careers and offer practical advice for those whose...
Psych Congress NP Institute...
03/28/2025
Psych Congress NP Institute
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Brittany Albright
Q&As
Evaluating Anhedonia With Patient-Centered Strategies
03/11/2025
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and...
03/11/2025
Psych Congress Network
Dr Brittany Albright
Q&As
Exploring Anhedonia in Psychiatric Care
03/04/2025
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress...
03/04/2025
Psych Congress Network

Quizzes

Expert Insights Quiz
Expert Insights Quiz
Effective Strategies to Introduce LAIs to Patients In-Person and Via Telemedicine
04/21/2025
Craig Chepke, MD, DFAPA
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following...
04/21/2025
Psych Congress Network
a dialogue bubble with the word "quiz"
Quiz
How do inpatient addiction consultation services impact MOUD initiation?
04/21/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
04/21/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
a sticky note that reads "take the quiz" stuck to a computer keyboard
Quiz
How does menopausal hormone therapy impact outomes in midlife women with schizophrenia?
04/11/2025
According to a 2024 study, what impact did MHT use have on the risk of psychosis relapse in women between ages 40 and 55?
According to a 2024 study, what impact did MHT use have on the risk of psychosis relapse in women between ages 40 and 55?
According to a 2024 study, what...
04/11/2025
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
By What Percentage Did US Drug Overdose Deaths Decline in 2024?
04/10/2025
According to provisional data from the Center for Disease Control and Prevention (CDC), by what percentage did US drug overdose deaths decrease in the 12 months ending in September 2024 compared to the previous year?
According to provisional data from the Center for Disease Control and Prevention (CDC), by what percentage did US drug overdose deaths decrease in the 12 months ending in September 2024 compared to the previous year?
According to provisional data...
04/10/2025
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network

Recent FDA Updates

FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
Increase in Suicidality Associated With FDA Black Box Warning Implementation
News
Increase in Suicidality Associated With FDA Black Box Warning Implementation
10/11/2024
Evi Arthur
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on...
10/11/2024
Psych Congress Network
FDA approval featuring craig chepke
News
FDA Approves First Schizophrenia Treatment in Over 3 Decades
09/27/2024
Meagan Thistle
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug...
09/27/2024
Psych Congress Network
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network

Live Meetings

Psych Congress Family & Friends Podcast

Rakesh and Craig
Podcasts
Weighing the Options: Medication, Lifestyle, and the Path to Wellness
03/26/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain...
03/26/2025
Psych Congress Network
psych congress family and friends podcast
Podcasts
Gut Feelings: Tackling Medication-Induced Nausea
02/05/2025
Join Dr Craig Chepke and D. Rakesh Jain in this episode of the Psych Congress Family & Friends Podcast as they tackle a topic that affects so many patients receiving psychiatric treatment: nausea!
Join Dr Craig Chepke and D. Rakesh Jain in this episode of the Psych Congress Family & Friends Podcast as they tackle a topic that affects so many patients receiving psychiatric treatment: nausea!
Join Dr Craig Chepke and D....
02/05/2025
Psych Congress Network
psych congress family and friends podcast
Podcasts
A New Beginning, and a Fond Farewell
01/06/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Join Dr Rakesh Jain and Dr Craig Chepke for a discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an exploration of a topic near and dear to Dr Maletic's heart—the role of norepinephrine in clinical practice.
Join Dr Rakesh Jain and Dr Craig Chepke for a discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an exploration of a topic near and dear to Dr Maletic's heart—the role of norepinephrine in clinical practice.
Join Dr Rakesh Jain and Dr Craig...
01/06/2025
Psych Congress Network
psych congress family and friends podcast
Podcasts
Welcome to Psych Congress Family & Friends Hosted by Rakesh Jain and Craig Chepke
01/06/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!
Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!
Introducing our new psychiatry...
01/06/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use